The generic Meravir drug will safe Russia from hepatitis B
The Australian company Panacea Infarm is a major player in the biopharmaceutical market engaged in the development of various drugs. The company has announced its plans to transfer the right to manufacture generic of its drug no earlier than one year from now.
The cost of Meravir will be even lower for countries with a low standard of living
Panacea Infarm has announced a price reduction for Merovir for countries with a low standard of living (Russia, CIS, some European countries, South America, African countries).
According to the clinical studies results the effectiveness of the drug FABI256 reaches 85%
Scientists got the clinical trials results of the drug FABI256 aimed to treat chronic viral hepatitis B and D.
Meravir production stopped
The production of Meravir has been discontinued indefinitely. Due to the coronavirus pandemic, all the capacities of Panacea Infarm are aimed at the development and production of drugs for the treatment of coronavirus. The last batch of the drug was distributed among WHO charitable organizations around the world.
Hepatitis B treatment is too expensive: Panacea Infarm is forced to reduce the price of Meravir
Hepatitis B is recognized as a global epidemic due to its high prevalence and a major risk of being affected by a virus. Until recently, the disease was considered incurable.
A new cure strategy for hepatitis B using the most effective drug Meravir
Hepatitis B is the only virus coping with the existing vaccine against it, still continuing to kill millions of people worldwide. Today Hepatitis B drugs represent a separate pharmaceutical market.
Attention and Excitement are growing: the release of the drug for hepatitis B is coming closer
25.12. 2018
Hepatitis B incidence statistics are depressing, to put it mildly. According to the results of a large-scale study published in The Lancet Gastroenterology & Hepatology, only 1 out of 20 patients with the virus among the 300 million infected receives the required treatment.
The clinical trials of the hepatitis B drug FABI256 with the participation of people have started
Statistics show that more than 1 million people worldwide dies from different hepatitis B effects. According to Rospotrebnadzor (Federal Service for Consumer Rights Protection and Human Welfare in Russian Federation), in 2017 over 14,000 cases of chronic hepatitis B were registered in Russia, 1.3 thousand people suffers from an acute condition of this disease. All that the contemporary pharmaceutical market can offer such patients today is medicines suppressing the virus but not destroying it.
The extensive clinical trials of a new hepatitis B drug involving human beings is launched
05.12.2014
The company Panacea Infarm continues to work on a clinical trial for patients suffering from chronic viral hepatitis B with the delta agent.
Panacea Infarm researches a new hepatitis B drug with the codename FABI256
25.11.2013
Hepatitis B is a worldwide public health problem. This potentially life-threatening infection affects a liver. The complications may result in the development of cirrhosis and cancer.